A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.
Zou X, Ding X, Feng ZK, Ouyang YF, Li HF, Wen K, Wang ZQ, Liu YP, Liu YL, Zhang WJ, Yang Q, Chen SY, Xie YL, Xie RQ, Lin C, Gu CM, Huang PY, Sun R, Hua YJ, You R, Chen MY.
Zou X, et al. Among authors: liu yp.
Cell Rep Med. 2024 Oct 15;5(10):101779. doi: 10.1016/j.xcrm.2024.101779.
Cell Rep Med. 2024.
PMID: 39413735
Free PMC article.
Clinical Trial.